Genmab Appoints Rodrigo Fernandez-Baca as General Manager, Italy and Spain

Copenhagen, Denmark – September 1, 2026

• Rodrigo Fernandez-Baca joins Genmab as the company expands its commercialization presence to Italy and Spain and prepares to deliver its innovative antibody-based medicines to more patients
• Rodrigo brings more than 20 years of international biotech and pharmaceutical leadership, with deep expertise in oncology, hematology, commercial execution, and in building high performing teams

Genmab A/S (Nasdaq: GMAB) today announced the appointment of Rodrigo Fernandez-Baca as General Manager, Italy and Spain, supporting the company’s continued growth in Europe to bring its innovative antibody-based medicines to more patients with cancer.

Founded in 1999 in Copenhagen, Genmab is an international biotechnology company specializing in antibody-based medicines. As General Manager, Rodrigo will oversee Genmab’s business in Italy and Spain, with responsibility for driving alignment, performance, and launch excellence to advance the company’s mission to improve the lives of patients with cancer and other serious diseases.

“We are delighted to welcome Rodrigo to Genmab. Italy and Spain are important markets in the next chapter of Genmab’s European growth, and Rodrigo brings the right combination of strategic acumen, oncology launch experience, and people leadership needed to establish strong in-market teams and advance our ambition to reach more patients with our innovative medicines,” said Margarida Duarte, Senior Vice President and General Manager, Europe and Emerging Markets, Genmab.

Rodrigo joins Genmab with more than 20 years of international biotech and pharmaceutical leadership experience, most recently with a specialized focus in oncology and hematology. He has held senior leadership positions at companies including Clovis Oncology, Seagen, and Pfizer, where he was responsible for overseeing broad oncology and hematology portfolio strategies across Spain, Italy, and France.

Earlier in his career, Rodrigo held senior leadership roles at Eli Lilly and Gilead Sciences where he led local and European commercialization strategies, built high-performing teams, and oversaw major product launches in Europe.

“What drew me to Genmab is the combination of bold science and a deep human purpose. I’m excited to be joining the company at such a pivotal moment in its growth, and to be part of the mission to help bring innovative antibody medicines to more patients who need them,” said Rodrigo Fernandez-Baca. “Italy and Spain are dynamic healthcare environments with highly committed oncology communities, and I look forward to working with our local teams and stakeholders to support Genmab’s continued expansion and patient impact.”

Rodrigo will be based in Milan, Italy, and will report to Margarida Duarte, Senior Vice President and General Manager, Europe and Emerging Markets.

About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit us on Genmab.com follow us on LinkedIn and X.

Contact

Solrun Sigfusdottir Øfjord, Director, Europe Commercialization Communications
T: +45 3144 0408; E: sosf@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

Forward-looking Statement
This Media Release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on Genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.